Noribogainalog


Noribogainalog, also known as 9-hydroxyibogaminalog, is a drug of the ibogalog family related to noribogaine. It is a simplified analogue of noribogaine.

Pharmacology

The drug acts as a potent serotonin 5-HT2A receptor partial agonist. It also has activity as a dopamine transporter chaperone. Noribogainalog does not affect locomotor activity, does not produce the head-twitch response, and does not affect various other physiological and behavioral measures. However, it does produce analgesic effects that can be diminished by the serotonin 5-HT2A receptor antagonist ketanserin. The drug shows relatively low expected blood–brain barrier permeability.

History

Noribogainalog was first described in the scientific literature by David E. Olson and colleagues by 2021.